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Valve ReplacementRandomized controlled trials of transcatheter aortic
valve replacement (TAVR) included both trans-
femoral and alternative access approaches for valve
delivery (1), but the best outcome, superiority to
surgical aortic valve replacement, was only achieved
in transfemoral patients (2,3). Unfortunately, a sig-
nificant number of patients remain ineligible for
routine transfemoral access due to peripheral arterial
disease, which precludes delivery of large-diameter
transcatheter valve delivery systems.
Intravascular lithotripsy (IVL) to facilitate trans-
femoral access was recently published as a case report
(4). To further understand the potential role of IVL in
patients deemed to have prohibitive iliofemoral
vascular disease, a multicenter registry was created to
prospectively study patients receiving IVL before
attempting transfemoral TAVR.
Between January and July 2018, 4 centers in Italy
and 4 centers in the United States established a
prospective case series of all patients undergoing
iliac or femoral arterial IVL (Shockwave Medical,
Santa Clara, California) to facilitate transfemoral
passage of delivery systems for TAVR. All patients
were required to have severe symptomatic aortic
valvular stenosis, at least intermediate risk of mor-
tality for surgical valve replacement, aortic valvular
anatomy compatible with safe implantation of
existing transcatheter valve sizes, and lower ex-
tremity vasculature deemed ineligible for standard
transfemoral access due to severe calcific peripheral
arterial occlusive disease. Inclusion was guided by
the pre-operative lower limb computed tomography
angiography.Vascular access, anticoagulation, introduction of
guidewires and catheters, and lower extremity angi-
ography were conducted according to standard best
care practices of each participating institution. The
use of pre-dilatation, balloon sizing, delivery of IVL
pulses, and provisional stenting were left to the
discretion of the operator. The primary study
endpoint was the success rate of transfemoral de-
livery of a TAVR system after IVL.
Forty-two consecutive patients were studied, and
results are summarized in Table 1. All patients ach-
ieved successful sheath passage and TAVR interven-
tion. Femoral access was achieved percutaneously in
>90% of patients. Reference vessel diameter was 8.1
mm, lesion minimum diameter 4.3 mm, with average
stenosis of 58.6%. Average maximum calcium arc was
265.5. Themajority of IVLwas performedwith a 7-mm
catheter (84.6%). No iliofemoral arterial perforation or
dissection requiring stent implantation was observed.
Vascular hemostasis was achieved with percutaneous
sutures >90% of the time. Access site complications
were low (4.6%) with 1 patient developing pseudoa-
neurysm and 1 requiring endarterectomy.
IVL, by disrupting intimal and medial calcification,
alters vessel compliance to allow for the safe passage
of large-bore delivery sheaths. This expands the pa-
tient cohort that could be eligible for transfemoral
access for TAVR procedures. IVL-enabled trans-
femoral access offers several advantages. First, it
preserves the established benefits of TAVR: decreased
morbidity and mortality, fewer hospital days, and
reduced cost. Second, although alternative access
options exist, they are more invasive and have a sig-
nificant learning curve (1,5). IVL leverages the famil-
iarity of a balloon-based intervention, minimizing the
learning curve regardless of a center’s volume.
In conclusion, IVL may represent a straightforward
technique to preserve the benefits of reduced
morbidity and mortality of transfemoral TAVR in






TABLE 1 Baseline Demographic and Lesion Characteristics and Procedural Outcomes
Baseline Characteristics (N ¼ 42) Procedural Details
(N ¼42)











Transfemoral valve delivery success 100 (42)




TAVR performed at same time as IVL 100 (42)







Baseline ejection fraction 52.6  12.4 IVL catheter size
5.0  60 mm
6.0  60 mm
6.5  60 mm
























































Target lesion diameter, mm* 4.3  1.1
Diameter stenosis, % 58.6  17.5
Target lesion length, mm† 37.4  23.3
Calcification, max arc† 265.5  88.3
Calcification, min CSA† 15.7  10.4
Values are % (n) or mean  SD. *Missing single data entry. †missing 2 to 4 data entries.
CSA ¼ cross-sectional area; IVL ¼ intravascular lithotripsy; TAVR ¼ transcatheter aortic valve replacement.
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